| CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2 D Bedognetti, TL Spivey, Y Zhao, L Uccellini, S Tomei, ME Dudley, ... British journal of cancer 109 (9), 2412-2423, 2013 | 145 | 2013 |
| Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma Q Xie, R Bradley, L Kang, J Koeman, ML Ascierto, A Worschech, ... Proceedings of the National Academy of Sciences 109 (2), 570-575, 2012 | 141 | 2012 |
| Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis TL Spivey, L Uccellini, ML Ascierto, G Zoppoli, V De Giorgi, LG Delogu, ... Journal of translational medicine 9, 1-22, 2011 | 97 | 2011 |
| An immunologic portrait of cancer ML Ascierto, VD Giorgi, Q Liu, D Bedognetti, TL Spivey, D Murtas, ... Journal of translational medicine 9, 1-13, 2011 | 97 | 2011 |
| Circulating let‐7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C K Matsuura, V De Giorgi, C Schechterly, RY Wang, P Farci, Y Tanaka, ... Hepatology 64 (3), 732-745, 2016 | 96 | 2016 |
| Pooled saliva specimens for SARS-CoV-2 testing B Barat, S Das, V De Giorgi, DK Henderson, S Kopka, AF Lau, T Miller, ... Journal of clinical microbiology 59 (3), 10.1128/jcm. 02486-20, 2021 | 67 | 2021 |
| IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes D Murtas, D Maric, V De Giorgi, J Reinboth, A Worschech, P Fetsch, ... British journal of cancer 109 (1), 76-82, 2013 | 65 | 2013 |
| Naturally acquired SARS-CoV-2 immunity persists for up to 11 months following infection V De Giorgi, KA West, AN Henning, LN Chen, MR Holbrook, R Gross, ... The Journal of Infectious Diseases 224 (8), 1294-1304, 2021 | 59 | 2021 |
| Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy CM Mousset, W Hobo, Y Ji, H Fredrix, V De Giorgi, RD Allison, ... Oncoimmunology 7 (10), e1488565, 2018 | 48 | 2018 |
| Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma V De Giorgi, A Monaco, A Worchech, ML Tornesello, F Izzo, L Buonaguro, ... Journal of translational medicine 7, 1-14, 2009 | 48 | 2009 |
| Melanoma NOS1 expression promotes dysfunctional IFN signaling Q Liu, S Tomei, ML Ascierto, V De Giorgi, D Bedognetti, C Dai, L Uccellini, ... The Journal of clinical investigation 124 (5), 2147-2159, 2014 | 47 | 2014 |
| Cardiac tamponade and heart failure due to myopericarditis as a presentation of infection with the pandemic H1N1 2009 influenza A virus SGPHNIVICHNTF Puzelli S, Buonaguro FM, Facchini M, Palmieri A, Calzoletti L ... J Clin Microbiol. 48 (6), 2298-300, 2010 | 44 | 2010 |
| mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants Y Yu, D Esposito, Z Kang, J Lu, AT Remaley, V De Giorgi, LN Chen, ... Scientific Reports 12 (1), 2628, 2022 | 40 | 2022 |
| IRF5 gene polymorphisms in melanoma L Uccellini, V De Giorgi, Y Zhao, B Tumaini, N Erdenebileg, ME Dudley, ... Journal of translational medicine 10, 1-8, 2012 | 39 | 2012 |
| Overexpression of HGF promotes HBV-induced hepatocellular carcinoma progression and is an effective indicator for Met-targeting therapy Q Xie, Y Su, K Dykema, J Johnson, J Koeman, V De Giorgi, A Huang, ... Genes & cancer 4 (7-8), 247-260, 2013 | 38 | 2013 |
| The immune-related role of BRAF in melanoma S Tomei, D Bedognetti, V De Giorgi, M Sommariva, S Civini, J Reinboth, ... Molecular oncology 9 (1), 93-104, 2015 | 33 | 2015 |
| The stable traits of melanoma genetics: an alternate approach to target discovery TL Spivey, V De Giorgi, Y Zhao, D Bedognetti, Z Pos, Q Liu, S Tomei, ... BMC genomics 13 (1), 1-11, 2012 | 30 | 2012 |
| Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis V De Giorgi, L Buonaguro, A Worschech, ML Tornesello, F Izzo, ... PLoS One 8 (2), e56153, 2013 | 22 | 2013 |
| Preferential association of hepatitis C virus with CD19+ B cells is mediated by complement system RY Wang, P Bare, V De Giorgi, K Matsuura, KA Salam, T Grandinetti, ... Hepatology 64 (6), 1900-1910, 2016 | 17 | 2016 |
| Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants Z Chen, P Zhang, Y Matsuoka, Y Tsybovsky, K West, C Santos, LF Boyd, ... MedRxiv, 2022.01. 12.22269023, 2022 | 16 | 2022 |
